Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SAN DIEGO, Nov. 03, 2016 -- Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its earnings for the third quarter ending September 30, 2016, before the market opens on Friday, November 11, 2016.
The company will hold a conference call and simultaneous webcast at 8:00 AM, Eastern Time (5:00 AM Pacific Time) to discuss the company's financial results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S) or (661) 378-9934 (international) using passcode 7817124. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m/p/r6on7ba8.
A replay of the call will be available through November 18, 11:00 AM EST by calling (855) 859-2056 (U.S.) or (404) 537-3406 (international), using passcode 7817124. An archive of the webcast will be available for twelve months following the event on Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN), is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics Inc.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
[email protected]
Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 1565
[email protected]
